- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00405392
Study To Investigate Patient Preference On Dosing In Ibandronate And Risedronate In Korean Women With Postmenopausal Osteoporosis
An Open-label, Multi-centre, Randomized Study to Investigate Patient Preference on Dosing in the Once-monthly Ibandronate and the Once-weekly Risedronate in Korean Women With Postmenopausal Osteoporosis. A Six-month, Two-sequence, and Two Period Crossover Study
This is a randomized open label, multi-centre study for Korean women with postmenopausal osteoporosis, evaluating the preference for either the once-monthly dosing of ibandronate or the once-weekly dosing of risedronate.
Eligible subjects will be randomised either ibandronate monthly regimen or risedronate weekly regimen.
Treatment period consists of 3 month with ibandronate 150mg and additional 12 week with risedronate 35 mg or vice versa.
After taking the first interventional medicine for 3 months or 12 weeks completely, a subject changes the treatment arm. There is no washout period.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 4
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Women with postmenopausal osteoporosis diagnosed by DXA scanning, defined by T-score of -2.5 SD at spine or femur.
- Patients who have never received bisphosphonates therapy (bisphosphonates naive)
Exclusion Criteria:
- Inability to stand or sit in the upright position for at least 60 minutes;
- Hypersensitivity to any component of risedronate and ibandronate;
- Administration of any investigational drug within 30 days preceding the first dose of the study drug;
- Patient has been on hormone (estrogen) replacement therapy or other osteoporosis medication (e.g. SERMS and calcitonin) within the previous 3 months.
- Patient has been on systemic corticosteroids therapy for more than 1 month within the past year.
- Other bone disease except osteoporosis
- Current medical history of uncontrolled major upper GI disease
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Ingen (Åben etiket)
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Percentage of Participants Who Prefer the Once-monthly Dosing of Ibandronate to the Once-weekly Dosing of Risedronate
Tidsramme: Visit 4 (Week 24)
|
Preference of monthly ibandronate and weekly risedronate was compared.
Modified-intention-to-treat (mITT) population was used for analysis.
Any participant randomly assigned, received the study drug, and participants were asked to fill the preference questionnaire on completion of study.
Preference was calculated as percentage.
Data for percentage of participants with preference to once-monthly dosing of ibandronate to the once-weekly dosing of risedronate was presented.
|
Visit 4 (Week 24)
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Percentage of Participants Choosing Ibandronate or Risedronate as Their Preferred Treatment Based on Convenience of Administration
Tidsramme: Visit 4 (Week 24)
|
Participant's preference for convenient treatment was compared between monthly ibandronate and weekly risedronate.
Analysis population was mITT.
Preference for convenient treatment was calculated as percentage.
Percentage of participants who think once-monthly ibandronate dosing is more convenient over once-weekly risedronate dosing were presented.
Those participants who answered the two treatments equally convenient were excluded while reporting.
|
Visit 4 (Week 24)
|
Mean Percent Change of Serum C-terminal Telopeptide (CTx) From Baseline to Visit 3 for Once-monthly Dosing of Ibandronate & Once-weekly Dosing of Risedronate
Tidsramme: Baseline (Week 0) and Visit 3 (Week 12)
|
The difference of change in serum CTX from basal value between the two sequences was tested using ANCOVA at 95% confidence interval at 3 months (Visit 3) after the administration.
Analysis was done with PP population.
Baseline was value at Week 0, Change from baseline was calculated by subtracting Baseline value from value at specified time point.
|
Baseline (Week 0) and Visit 3 (Week 12)
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 109393
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Osteoporose, postmenopausal
-
Mayo ClinicAfsluttetPostmenopausalForenede Stater
-
Hend HamdyIkke rekrutterer endnu
-
University of Erlangen-Nürnberg Medical SchoolElsbeth-Bonhoff-Stiftung, BerlinAfsluttetPostmenopausalTyskland
-
Warner ChilcottSanofiAfsluttetPostmenopausalForenede Stater, Polen, Canada, Kroatien, Holland
-
Riphah International UniversityAfsluttetPostmenopausal osteoporose | Postmenopausal osteopeniPakistan
-
AmgenAfsluttetPostmenopausal osteoporose (PMO)Japan
-
University Hospital Inselspital, BerneRekrutteringPostmenopausal | Postmenopausal rødmenSchweiz
-
University Health Network, TorontoCanadian Institutes of Health Research (CIHR)AfsluttetPostmenopausal osteoporose | Postmenopausal osteopeniCanada
-
Deltanoid PharmaceuticalsAfsluttetPostmenopausal osteoporose, flere steder
-
Jae Hoon LeeGachon University Gil Medical Center; Daejeon UniversityUkendtPostmenopausal periodeKorea, Republikken
Kliniske forsøg med Ibandronate (SB743830HD)
-
GlaxoSmithKlineAfsluttetOsteoporoseKorea, Republikken
-
Hoffmann-La RocheAfsluttetSmerte | Neoplasma Metastase | KnogleneoplasmaForenede Stater, Mexico, Tyskland, Den Russiske Føderation, Italien, Ungarn, Belgien, Chile, Frankrig, Argentina, Australien, Schweiz, Guatemala, Puerto Rico, Polen, Panama, Det Forenede Kongerige, Canada
-
Hoffmann-La RocheTrukket tilbageSmerte | Neoplasma Metastase | KnogleneoplasmaGrækenland
-
Hoffmann-La RocheAfsluttetSmerte; Knogleneoplasmer; Neoplasma MetastaseKalkun
-
Chinese Society of Lung CancerAfsluttet
-
Chinese University of Hong KongAfsluttetSystemisk lupus erythematosusKina
-
Hoffmann-La RocheAfsluttetSmerte | Neoplasma Metastase | KnogleneoplasmaForenede Stater, Italien, Chile, Den Russiske Føderation, Ungarn, Det Forenede Kongerige, Polen, Guatemala, Tyskland, Mexico, Puerto Rico, Grækenland, Australien, Schweiz, Argentina, Panama
-
University Hospital, Basel, SwitzerlandAfsluttetOsteonekrose i knæet | Knoglemarvsødem i knæetSchweiz
-
University Hospital, LinkoepingAfsluttet